ÈËÆÞÖгöÊÓƵ

Guillaume Lamotte
( out of 164 reviews )

Guillaume Lamotte, MD, MSc

Languages spoken: English, French

Clinical Locations

Imaging & Neurosciences Center

Salt Lake City
801-585-7575

  • Dr. Lamotte has a broad background in medicine and neurology with specialty training and expertise in movement disorders and autonomic disorders. He completed a neurology residency at the ÈËÆÞÖгöÊÓƵ Hospital of Caen in France and did a year of supplementary training in movement disorders during his first neurology residency. He then completed the clinician-scientist track between the National Institutes of ÈËÆÞÖгöÊÓƵ (NIH) and Medstar Georgetown ÈËÆÞÖгöÊÓƵ Hospital as his second neurology residency in the United States. He worked under the guidance of Dr. David Goldstein in the autonomic medicine section at the NIH and developed his clinical skills in autonomic medicine through history taking and physical examinations, as well as exposure to autonomic function testing procedures. He gained experience in conducting clinical research in autonomic disorders focusing on autonomic nervous system dysfunction in synucleinopathies. He completed a clinical fellowship at the Mayo Clinic in Rochester, MN, where he had a broad exposure to various autonomic disorders in the clinic and autonomic laboratory. He is pursuing an academic career focused on clinical research in the fields of autonomic and movement disorders and is currently an assistant professor in neurology at the ÈËÆÞÖгöÊÓƵ of Utah, Salt Lake City, UT, where he sees patients with movement disorders and autonomic disorders.

    Specialties

    Board Certification

    American Board of Psychiatry & Neurology (Neurology)
    Educational Commission for Foreign Medical Graduates
    National Board of Medical Examiners
    United Council for Neurologic Subspecialties (Autonomic Disorders)

    Patient Rating

    4.9 /5
    ( out of 164 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 21, 2024
    CLINICAL NEUROSCIENCES CENTER

    Dr Lamotte seemed to care about my care. He ordered more blood tests to help find a answer to my health problems

    July 04, 2024
    CLINICAL NEUROSCIENCES CENTER

    Dr. Lamotte is very personable and easy to talk to and ask questions. He puts you at ease and is very patient.

    July 03, 2024
    CLINICAL NEUROSCIENCES CENTER

    Very caring and obviously concerned about your health and happiness.

    June 27, 2024
    CLINICAL NEUROSCIENCES CENTER

    Very professional listens to your concerns and speaks to you in a way that is easy to understand.

    June 27, 2024
    CLINICAL NEUROSCIENCES CENTER

    Great doctor...always willing to listen and engage in understanding the patient's issues. He is a hands-on doctor. By that (hands-on), I mean he is actively listening and evaluating patient needs, and his interactions with me, the patient, were not rushed and alternatives were always provided.

    June 21, 2024
    CLINICAL NEUROSCIENCES CENTER

    Muy cortés es el Dr. Lamotte.

    June 20, 2024
    CLINICAL NEUROSCIENCES CENTER

    Very personable. Great at explaining in clear termst

    June 07, 2024
    CLINICAL NEUROSCIENCES CENTER

    Outstanding Dr.

    June 06, 2024
    CLINICAL NEUROSCIENCES CENTER

    A very good doctor

    See More Patient Comments

  • Dr. Lamotte has a broad background in medicine and neurology with specialty training and expertise in movement disorders and autonomic disorders. He completed a neurology residency at the ÈËÆÞÖгöÊÓƵ Hospital of Caen in France and did a year of supplementary training in movement disorders during his first neurology residency. He then completed the clinician-scientist track between the National Institutes of ÈËÆÞÖгöÊÓƵ (NIH) and Medstar Georgetown ÈËÆÞÖгöÊÓƵ Hospital as his second neurology residency in the United States. He worked under the guidance of Dr. David Goldstein in the autonomic medicine section at the NIH and developed his clinical skills in autonomic medicine through history taking and physical examinations, as well as exposure to autonomic function testing procedures. He gained experience in conducting clinical research in autonomic disorders focusing on autonomic nervous system dysfunction in synucleinopathies. He completed a clinical fellowship at the Mayo Clinic in Rochester, MN, where he had a broad exposure to various autonomic disorders in the clinic and autonomic laboratory. He is pursuing an academic career focused on clinical research in the fields of autonomic and movement disorders and is currently an assistant professor in neurology at the ÈËÆÞÖгöÊÓƵ of Utah, Salt Lake City, UT, where he sees patients with movement disorders and autonomic disorders.

    Board Certification and Academic Information

    Academic Departments Neurology -Primary
    Board Certification
    American Board of Psychiatry & Neurology (Neurology)
    Educational Commission for Foreign Medical Graduates
    National Board of Medical Examiners
    United Council for Neurologic Subspecialties (Autonomic Disorders)

    Education history

    Fellowship Autonomic Disorders - Mayo Clinic Fellow
    Neurology - National Institutes of ÈËÆÞÖгöÊÓƵ / MedStar Georgetown ÈËÆÞÖгöÊÓƵ Hospital Academic Chief Resident
    Residency Neurology (Clinician Scientist Track) - National Institutes of ÈËÆÞÖгöÊÓƵ / MedStar Georgetown ÈËÆÞÖгöÊÓƵ Hospital Resident
    Internal Medicine - National Institutes of ÈËÆÞÖгöÊÓƵ / MedStar Georgetown ÈËÆÞÖгöÊÓƵ Hospital Resident
    Graduate Training Neurosciences - ÈËÆÞÖгöÊÓƵ of Caen M.S.
    Movement Disorders - Groupe Hospitalier Pitié Salpêtrière, Paris, France Diploma
    Residency Neurology - ÈËÆÞÖгöÊÓƵ Hospital of Caen Basse Normandie Resident
    Medicine - ÈËÆÞÖгöÊÓƵ of Caen Basse-Normandie M.D.
    Graduate Training Anatomy - ÈËÆÞÖгöÊÓƵ of Caen Basse-Normandie M.S.
    Infectious Disease and Tropical Disease - ÈËÆÞÖгöÊÓƵ of Caen Basse-Normandie M.S.

    Selected Publications

    Journal Article

    1. Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, Agarwal P, Aldridge GM, Barboi A, Evidente VGH, Galasko D, Geschwind MD, Gonzalez-Duarte A, Gil R, Gudesblatt M, Isaacson SH, Kaufmann H, Khemani P, Kumar R, Lamotte G, Liu AJ, McFarland NR, Miglis M, Reynolds A, Sahagian GA, Saint-Hillaire MH, Schwartzbard JB, Singer W, Soileau MJ, Vernino S, Yerstein O, Freeman R (2024). Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies. JAMA. ()
    2. Earl T, Jridi A, Thulin PC, Zorn M, McKee KE, Mitrovich K, Moretti P, Alshaikh J, Kassavetis P, Cortez MM, Lamotte G (2024). Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study. Clin Auton Res, 34(1), 117-124. ()
    3. Rasmussen TK, Borghammer P, Finnerup NB, Jensen TS, Hansen J, Knudsen K, Singer W, Lamotte G, Terkelsen AJ (2024). Functional and (123)I-MIBG scintigraphy assessment of cardiac adrenergic dysfunction in diabetes. Auton Neurosci, 252, 103155. ()
    4. Griffith G, Lamotte G, Mehta N, Fan P, Nikolich J, Springman V, Suttman E, Joslin E, Balfany K, Dunlap M, Kohrt WM, Christiansen CL, Melanson EL, Josbeno D, Chahine LM, Patterson CG, Corcos DM (2024). Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson's Disease. J Parkinsons Dis. ()
    5. Corcos DM, Lamotte G, Luthra NS, McKee KE (2023). Advice to People with Parkinson's in My Clinic: Exercise. J Parkinsons Dis. ()
    6. Lenka A, Lamotte G, Beach P (2023). Asymptomatic orthostatic hypotension in synucleinopathies: to treat or not to treat? Clin Auton Res. ()
    7. Lamotte G, Sandroni P (2022). Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies. Curr Neurol Neurosci Rep, 22(12), 823-837. ()
    8. Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, SchwarzsÈËÆÞÖгöÊÓƵ MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM, SPARX3-PSG Investigators (2022). Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials, 23(1), 855. ()
    9. Lamotte G, Lenka A (2022). Orthostatic Hypotension in Parkinson Disease: What Is New? Neurol Clin Pract, 12(5), e112-e115. ()
    10. Lenka A, Di Maria G, Lamotte G, Bahroo L, Jankovic J (2022). Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother, 22(6), 489-498. ()
    11. Lamotte G, Coon EA, Suarez MD, Sandroni P, Benarroch E, Cutsforth-Gregory JK, Mauermann ML, Berini SE, Shouman K, Sletten D, Goodman BP, Low PA, Singer W (2021). Standardized Autonomic Testing in Patients With Probable Radiation-Induced Afferent Baroreflex Failure. Hypertension, 79(1), 50-56. ()
    12. Castillo-Pinto C, Lamotte G, Mehta A, Sonti R, Di Maria G, Ruiz D, Kumar PN, Stemer AB, Denny MC (2020). ÈËÆÞÖгöÊÓƵcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection. Neurohospitalist, 12(1), 48-56. ()
    13. Goldstein DS, Isonaka R, Lamotte G, Kaufmann H (2021). Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies. Clin Auton Res, 31(6), 677-684. ()
    14. Lamotte G, Shouman K, Benarroch EE (2021). Stress and central autonomic network. Auton Neurosci, 235, 102870. ()
    15. Laureno R, Lamotte G (2022). The midline cerebellar lesion in experimental Wernicke disease. Neurol India, 69(6), 1624. ()
    16. Lamotte G, Sandroni P, Cutsforth-Gregory JK, Berini SE, Benarroch EE, Shouman K, Mauermann ML, Anderson J, Low PA, Singer W, Coon EA (2021). Clinical presentation and autonomic profile in Ross syndrome. J Neurol, 268(10), 3852-3860. ()
    17. Lamotte G, Sandroni P (2021). A practical approach to peripheral autonomic neuropathies. Curr Opin Neurol, 34(5), 638-647. ()
    18. Lamotte G, Takahashi M, Wu T, Sullivan P, Cherup J, Holmes C, Goldstein DS (2021). Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases? Clin Auton Res, 31(4), 543-551. ()
    19. Lamotte G (2021). Central pontine myelinolysis secondary to rapid correction of hyponatremia historical perspective with Doctor Robert Laureno. Neurol Sci, 42(8), 3479-3483. ()
    20. Lamotte G, Coon EA, Suarez MD, Sandroni P, Benarroch EE, Cutsforth-Gregory JK, Mauermann ML, Berini SE, Shouman K, Sletten D, Goodman BP, Low PA, Singer W (2021). Natural History of Afferent Baroreflex Failure in Adults. Neurology, 97(2), e136-e144. ()
    21. Goldstein DS, Sullivan P, Holmes C, Lamotte G, Lenka A, Sharabi Y (2021). Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. J Neurochem, 158(2), 554-568. ()
    22. Shouman K, Vanichkachorn G, Cheshire WP, Suarez MD, Shelly S, Lamotte GJ, Sandroni P, Benarroch EE, Berini SE, Cutsforth-Gregory JK, Coon EA, Mauermann ML, Low PA, Singer W (2021). Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res, 31(3), 385-394. ()
    23. Lenka A, Mittal SO, Lamotte G, Pagan FL (2020). A Pragmatic Approach to the Perioperative Management of Parkinson's Disease. Can J Neurol Sci, 48(3), 299-307. ()
    24. Lamotte G, Benarroch EE (2021). What Is the Clinical Correlation of Cardiac Noradrenergic Denervation in Parkinson Disease? Neurology, 96(16), 748-753. ()
    25. Lenka A, Lamotte G, Goldstein DS (2021). Cardiac 18F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA. Mov Disord Clin Pract, 8(4), 582-586. ()
    26. Lamotte G, Lenka A (2021). Brainstem Predominant Posterior Reversible Encephalopathy Syndrome. Neurol India, 69(2), 536-537. ()
    27. Lamotte G, Holmes C, Sullivan P, Lenka A, Goldstein DS (2020). Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Ann Clin Transl Neurol, 7(12), 2450-2460. ()
    28. Castillo-Pinto C, Lamotte G, et al (2020). ÈËÆÞÖгöÊÓƵcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection. Neurohospitalist.
    29. Lamotte G, Holmes C, Wu T, Goldstein DS (2019). Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord, 67, 27-33. ()
    30. Lamotte G, Holmes C, Sullivan P, Goldstein DS (2018). Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Clin Auton Res, 29(1), 113-117. ()
    31. Laureno R, Lamotte G, Mark AS (2018). Sequential MRI in pontine and extrapontine myelinolysis following rapid correction of hyponatremia. BMC Res Notes, 11(1), 707. ()
    32. Lamotte G (2018). Author response: Mystery Case: A case of fulminant encephalopathy in a 69-year-old woman. Neurology, 90(15), 714. ()
    33. Lamotte G, Farzal Z, Zimmerman WD, Han S, de Brito P, Mayson D (2017). Clinical Reasoning: Monocular vision loss, ophthalmoplegia, and strokes in a 61-year-old man with diabetes mellitus. Neurology, 89(24), e276-e281. ()
    34. Lamotte G, Williams C (2017). Mystery Case: A case of fulminant encephalopathy in a 69-year-old woman. Neurology, 89(9), e109-e114. ()
    35. Lamotte G, Shah RC, Lazarov O, Corcos DM (2016). Exercise Training for Persons with Alzheimer's Disease and Caregivers: A Review of Dyadic Exercise Interventions. J Mot Behav, 49(4), 365-377. ()
    36. Lamotte G, Agostini D (2015). Erratum to: Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism? J Nucl Cardiol, 24(1), 111. ()
    37. Lamotte G, Morello R, Lebasnier A, Agostini D, Bouvard G, De La Sayette V, Defer GL (2016). Influence of education on cognitive performance and dopamine transporter binding in dementia with Lewy bodies. Clin Neurol Neurosurg, 146, 138-43. ()
    38. Lebasnier A, Lamotte G, Manrique A, Peyronnet D, Bouvard G, Defer G, Agostini D (2015). Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases. Eur J Nucl Med Mol Imaging, 42(7), 1043-51. ()
    39. Lamotte G, Morello R, Lebasnier A, Agostini D, Defer GL (2015). Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses. BMC Neurol, 15, 83. ()
    40. Lamotte G, Skender E, Rafferty MR, David F, Sadowsky S, Corcos DM (2015). Effects of progressive resistance exercise training on the motor and non-motor features of Parkinson’s disease: a review. 4, 11-27.
    41. Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM (2014). Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review. J Parkinsons Dis, 5(1), 21-41. ()

    Review

    1. Lamotte G, Singer W (2023). Synucleinopathies. [Review]. Handb Clin Neurol, 196, 175-202. ()

    Book Chapter

    1. Guillaume Lamotte, Norman L Foster (2023). Appropriate Use of Biomarkers in Suspected Neurodegenerative Diseases. In Donna J. Cross, Karina Mosci, Satoshi Minoshima (Eds.), Molecular Imaging of Neurodegenerative Disorders (1). Springer.

    Editorial

    1. Lamotte G (2023). Recent updates in autonomic research: new insights into vagal nerve activity during exercise, cardiac autonomic neuropathy and silent myocardial infarction in diabetes, and timing of orthostatic blood pressure change and future risk of dementia. Clin Auton Res, 33(6), 619-621. ()
    2. Lamotte G, Kaufmann H, Jordan J (2022). The Clinical Autonomic Research journal 2022 and onward. Clin Auton Res, 33(1), 1-2. ()
    3. Baker JR, Bourne KM, Lamotte G (2023). Recent updates in autonomic research: a focus on new technologies with high-resolution procedures to study sympathetic nerve activity, plasma proteomic profiling in POTS, and non-invasive neuromodulation with focused ultrasound. Clin Auton Res, 33(1), 11-14. ()
    4. Lamotte G, Cheshire WP (2022). Do not forget about caregivers in autonomic medicine! Clin Auton Res, 32(6), 403-404. ()
    5. Lamotte G, Kaufmann H (2022). Movement disorder society criteria for the diagnosis of multiple system atrophy-what's new? Clin Auton Res, 32(3), 163-165. ()
    6. Lamotte G, Goldstein DS (2022). What new can we learn from cardiac sympathetic neuroimaging in synucleinopathies? Clin Auton Res. ()
    7. Lamotte G, Millar Vernetti P (2021). Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: is this the end of the story? Clin Auton Res, 31(6), 645-647. ()
    8. Lamotte G, Boes CJ, Low PA, Coon EA (2021). The expanding role of the cold pressor test: a brief history. Clin Auton Res, 31(2), 153-155. ()
    9. Lamotte G, Becker B (2020). Toward biomarker-based clinical subtyping of Parkinson disease. Neurology, 95(11), 461-462. ()
    10. Guillaume L, Denis A (2015). Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism? J Nucl Cardiol, 24(1), 108-110. ()

    Letter

    1. Zahid A, Coon EA, Lamotte G (2021). "No man is an island"-unique pattern of anhidrosis with islands of preserved sweat in Ross syndrome. [Letter to the editor]. Neurol Sci, 42(12), 5399-5400. ()
    2. Cutsforth-Gregory JK, Benarroch EE, Lamotte G (2021). Platypnea-orthodeoxia syndrome mimicking postural orthostatic tachycardia syndrome. [Letter to the editor]. Clin Auton Res, 31(4), 573-576. ()
    3. Lamotte G, Sandroni P (2021). A case of Ross syndrome associated with systemic sclerosis. [Letter to the editor]. Clin Auton Res, 31(3), 463-465. ()
    4. Lamotte G, Benarroch EE, Coon EA (2021). Paroxysmal hypothermia and hyperhidrosis with exacerbation after COVID-19 Infection. [Letter to the editor]. Clin Auton Res, 31(2), 327-329. ()
    5. Chochol MD, Kataria L, ORourke MC, Lamotte G (2019). Clozapine-Associated Myoclonus and Stuttering Secondary to Smoking Cessation and Drug Interaction: A Case Report. [Letter to the editor]. J Clin Psychopharmacol, 39(3), 275-277. ()
    6. Lamotte G, Laballe R, Dupuy B (2014). Bilateral eyelid retraction, loss of vision, ophthalmoplegia: an atypical triad in anti-GQ1b syndrome. [Letter to the editor]. Rev Neurol (Paris), 170(6-7), 469-70. ()
    7. Lamotte G, Caillot A, Di Palma C, Lechapt-Zalcman E, Benateau H, Cogez J (2014). Intramedullary metastasis of a cutaneous squamous cell carcinoma. [Letter to the editor]. Rev Neurol (Paris), 170(3), 230-2. ()
    8. Lamotte G, Danaila TC, Jaillon-Rivire V, Hitier M, Defer GL (2013). Paraneoplastic opsoclonus myoclonus with autoantibodies to glutamic acid decarboxylase. [Letter to the editor]. Rev Neurol (Paris), 170(1), 50-1. ()
    9. Lamotte G, Cogez J, Viader F (2012). Interferon-β-1a-induced psychosis in a patient with multiple sclerosis. [Letter to the editor]. Psychiatry Clin Neurosci, 66(5), 462. ()

    Other

    1. Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM (2015). Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review. J Parkinsons Dis (5(4), p. 993). Netherlands. ()

  • News & Podcasts

    News